Peptides DB
Research-centric peptide and protocol reference hub
Study 60 of 65HCG (Human Chorionic Gonadotropin) literaturebiorxiv-preprint · Case report2023

High-grade endometrioid carcinoma arising from uterine serosal endometriosis with focal choriocarcinomatous differentiation and embryonal carcinoma-like morphology: a case report and literature review

This case highlights that malignant transformation of endometriosis can exhibit unusual differentiation patterns, and normal serum β-hCG levels do not rule out significant disease.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the hcg (human chorionic gonadotropin) corpus
9
Preclinical
51
Observational · this one
0
Open-label
3
Randomised
2
Reviews

Summary and findings

A 54-year-old postmenopausal woman presented with postmenopausal vaginal bleeding and a pelvic mass. The patient underwent emergency surgery revealing a 12-cm pelvic mass diagnosed as high-grade endometrioid carcinoma with choriocarcinomatous differentiation. Postoperative treatment included five cycles of adjuvant BEP chemotherapy.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Serum β-hCG remained persistently below 1 mIU/mL throughout follow-up.n=12023

Abstract

The authors’ words, as biorxiv-preprint supplied them

<title>Abstract</title> <p> <bold>Background</bold> Malignant transformation of endometriosis is uncommon and most frequently results in endometrioid carcinoma or clear cell carcinoma. Choriocarcinomatous differentiation arising in endometriosis-associated carcinoma is exceptionally rare, and the clinical characteristics and optimal management strategies remain unclear. We report a rare case of high-grade endometrioid carcinoma arising from uterine serosal endometriosis with focal choriocarcinomatous and embryonal carcinoma-like differentiation. <bold>Case presentation</bold> A 54-year-old postmenopausal woman presented with postmenopausal vaginal bleeding for more than 50 days and rapid enlargement of a pelvic mass. Preoperative serum AFP and CA125 were mildly elevated, whereas serum β-hCG remained persistently below 1 mIU/mL throughout follow-up. After radiological and hysteroscopic evaluation, emergency surgery was performed because of clinical deterioration. A 12-cm pelvic mass invading the sigmoid colon was identified intraoperatively. Histopathological examination demonstrated malignant transformation arising from uterine serosal endometriosis, diagnosed as high-grade endometrioid carcinoma with aberrant p53 immunostaining, accompanied by focal choriocarcinomatous differentiation and focal embryonal carcinoma-like morphology. The patient received five cycles of adjuvant BEP chemotherapy postoperatively. Brain metastasis developed during follow-up and was treated with radiotherapy. Retroperitoneal lymph node metastasis subsequently occurred, and second-line chemotherapy with nab-paclitaxel plus carboplatin was administered. Dynamic serum tumour marker changes correlated with disease burden, whereas serum β-hCG remained negative. Histological confirmation of metastatic lesions was unavailable. <bold>Conclusions</bold> This case highlights that malignant transformation of postmenopausal uterine serosal endometriosis may rarely exhibit divergent differentiation, including choriocarcinomatous differentiation, despite persistently normal serum β-hCG levels. Aberrant p53 expression may be associated with tumour progression and lineage plasticity, although its biological significance requires further investigation. Individualized multimodal surveillance may be considered for this rare entity, as optimal follow-up strategies remain undefined. </p>

Background

Malignant transformation of endometriosis is uncommon, typically resulting in endometrioid or clear cell carcinoma. Choriocarcinomatous differentiation in endometriosis-associated carcinoma is exceptionally rare, with unclear clinical characteristics and management strategies. This case report provides insight into a rare instance of high-grade endometrioid carcinoma with divergent differentiation.

Methods

The study presents a case report of a 54-year-old postmenopausal woman with a pelvic mass and elevated tumor markers. The patient underwent emergency surgery after radiological and hysteroscopic evaluation. Histopathological examination confirmed high-grade endometrioid carcinoma with choriocarcinomatous differentiation.

Results

The primary endpoint was the identification of a 12-cm pelvic mass invading the sigmoid colon, with histopathological confirmation of high-grade endometrioid carcinoma. Serum β-hCG levels remained below 1 mIU/mL throughout follow-up, and aberrant p53 expression was noted.

Interpretation

This case adds to the limited literature on malignant transformation in endometriosis, particularly highlighting the potential for divergent differentiation. The effect size regarding tumor markers and histological findings is significant but requires further investigation to establish clinical relevance. Limitations include the single-patient nature of the report and the lack of histological confirmation for metastatic lesions.

Key findings

  • Patient presented with postmenopausal vaginal bleeding for more than 50 days.
  • Serum AFP and CA125 were mildly elevated; serum β-hCG remained below 1 mIU/mL.
  • A 12-cm pelvic mass invading the sigmoid colon was identified intraoperatively.
  • Histopathological examination diagnosed high-grade endometrioid carcinoma with aberrant p53 immunostaining.
  • The patient received five cycles of adjuvant BEP chemotherapy postoperatively.

Limitations

  • Single case report limits generalizability.
  • Histological confirmation of metastatic lesions was unavailable.
  • No long-term follow-up data reported.

Elsewhere in the HCG (Human Chorionic Gonadotropin) corpus

BEarly pembrolizumab as salvage therapy in EMA-CO-refractory ultra-high-risk gestational choriocarcinoma.Seminars in oncology · 2026 · n=1 · Not reported in abstract.HumanBEndometrial ultrasound features associated with methotrexate success in tubal ectopic pregnancy: a prospective case series.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2024 · n=177 · Treatment success occurred in 94 of 177 women (53.1%).HumanBSuccessful fertility-preserving management of a viable cesarean scar ectopic pregnancy: a case report.Case reports in women's health · 2026 · n=1 · Estimated blood loss of 20 mL.HumanBEndometrial ultrasound features associated with methotrexate success in tubal ectopic pregnancy: a prospective case series.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2026 · 53.1% treatment success in 177 women.HumanCSR-18292 Alters Oocyte Competence and Ovarian Transcriptomic Dynamics in Female Micebiorxiv-preprint · 2026 · Not reported in abstract.AnimalBEfficacy of hysteroscopic curettage and niche resection in type II and III cesarean scar pregnancies.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2026 · n=105 · 20 (15,25) min vs 25 (20,31) min operation time, p=0.001Human